NCT01822873

Brief Summary

The study hypothesis is that patients with dry age-related macular degeneration experience visual function impairments such as defects in dark adaptation, glare intolerance, poor light transition and reading in low lighting conditions. Studies have shown that patients in the early phases of AMD with normal visual acuity commonly reported difficulty with these visual functions but there have been no systematic studies evaluating these deficits in this population. This prospective, exploratory study will include up to 130 patients with dry AMD and 60 controls. These patients will undergo the following non-invasive visual function testing:

  • microperimetry with eye tracking
  • low luminance visual acuity
  • specialized color vision (cone-specific)
  • contrast testing and night vision testing. High-resolution spectral domain optical coherence tomography (SDOCT) images will be taken of the central retina using the Spectralis OCT unit. The values of visual function tested will be correlated with the findings on SDOCT (volume/amount of drusen present in early AMD). There are no known risks to the subjects beyond what is normal for standard examinations of the eye, visual function testing and standard ocular photographic procedures.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
128

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2013

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

March 28, 2013

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 2, 2013

Completed
5.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

April 17, 2019

Status Verified

February 1, 2019

Enrollment Period

5.3 years

First QC Date

March 28, 2013

Last Update Submit

April 15, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in low luminance visual acuity

    Arm 1: 1-2 months. Arm 2: 6, 12, 18 and 24 months

Secondary Outcomes (3)

  • Change in cone specific contrast sensitivity

    Arm 1: 1-2 months. Arm 2: 6, 12, 18 and 24 months

  • Change in contrast sensitivity

    Arm 1: 1-2 months. Arm 2: 6, 12, 18 and 24 months

  • Change in macular sensitivity on microperimetry

    Arm 1: 1-2 months. Arm 2: 6, 12, 18 and 24 months

Study Arms (2)

Normal

Age-related macular degeneration

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects will be identified from patients of the Duke Eye Center presenting for ophthalmologic consultation. Patients with dry AMD are routinely available from this clinic and will be the primary study group.

You may qualify if:

  • Capable and willing to provide consent
  • Has been diagnosed with dry age-related macular degeneration stages 1-3
  • At least 50 years of age

You may not qualify if:

  • Unable or unwilling to give consent
  • Under 50 years of age
  • Presence of retinal pathology such as central geographic atrophy, hemorrhage or retinal fluid, and other macular pathology other than AMD
  • Presence of dense cataracts in the study eye(s) that can affect visual function tests
  • Presence of glaucoma requiring treatment during the study and/or visual field defects
  • Presence retinal laser or surgical theraphy in study eye (s)
  • Any of other ocular condition requiring long-term theraphy or surgery during the study
  • Participant has photographically significant corneal or media opacities in either eye that would preclude adequate ophthalmic imaging and functional testing
  • Diagnosis of nystagmus that will interfere with testing
  • High myopia -8 Diopters or more severe
  • Participant has, in the opinion of the Investigator, any physical or mental condition that would increase the risk of participation in the stduy or may interfere with the study procedures, evaluations and outcome assessments.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke Eye Center

Durham, North Carolina, 27710, United States

Location

Related Publications (2)

  • Cocce KJ, Stinnett SS, Luhmann UFO, Vajzovic L, Horne A, Schuman SG, Toth CA, Cousins SW, Lad EM. Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints. Am J Ophthalmol. 2018 May;189:127-138. doi: 10.1016/j.ajo.2018.02.012. Epub 2018 Mar 15.

  • Thompson AC, Luhmann UFO, Stinnett SS, Vajzovic L, Horne A, Toth CA, Cousins SW, Lad EM. Association of Low Luminance Questionnaire With Objective Functional Measures in Early and Intermediate Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):289-297. doi: 10.1167/iovs.17-22528.

MeSH Terms

Conditions

Macular Degeneration

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Study Officials

  • Eleonora Lad, MD, PhD

    Duke University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 28, 2013

First Posted

April 2, 2013

Study Start

March 1, 2013

Primary Completion

July 1, 2018

Study Completion

July 1, 2018

Last Updated

April 17, 2019

Record last verified: 2019-02

Locations